Abiopharma

News list

Yocca Frank 🟡 adjusted position in 0 shares (1 derivative) of BioXcel Therapeutics, Inc. (BTAI) Transaction Date: May 01, 2026 | Filing ID: 057365

Full text

News bot May 7, 2026, 11:01 p.m.
🔍 Yocca Frank (Executive)

Company: BioXcel Therapeutics, Inc. (BTAI)

Report Date: 2026-05-01
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 9,000
- Total shares sold: 9,000
Detailed Transactions and Holdings:
- Acquired 9,000 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 15,520.00 | transaction_form_type: 4 | Footnotes: F1
- Sold 9,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2, F2
Footnotes:
- F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- F2: On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date.